Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany
The PRediction of short-term Outcome in preGNant wOmen with Suspected preeclampsIa Study (PROGNOSIS) demonstrated that a soluble fms-like tyrosine kinase 1/placental growth factor (sFlt-1/PlGF) ratio ≤ 38 ruled out the occurrence of preeclampsia in the next week with a negative predictive value of 99.3%; a ratio > 38 indicates an increased risk of developing preeclampsia in the next 4 weeks. We performed an assessment of the economic impact of the sFlt-1/PlGF ratio test for short-term prediction of preeclampsia in Germany.
We adapted a cost-effectiveness model, which had been developed to estimate the incremental value of adding the sFlt-1/PlGF ratio test with a cut-off ratio of 38 to standard diagnostic procedures for guiding the management of women with suspected preeclampsia in the UK. We used the adapted model to estimate the incremental value of the sFlt-1/PlGF ratio test (cut-off 38) for guiding the management of women with suspected preeclampsia from a German Diagnosis-Related Group (DRG) payer perspective. The economic model estimated costs associated with diagnosis and management of preeclampsia in women managed in either a ‘no-test’ scenario in which clinical decisions are based on standard diagnostic procedures alone, or a ‘test’ scenario in which the sFlt-1/PlGF test is used in addition to standard diagnostic procedures. Test characteristics and rates of hospitalization were derived from patient-level data from PROGNOSIS. The main outcome measure from the economic model was the total cost per patient.
In the model adapted to the German DRG payer system, introduction of the sFlt-1/PlGF ratio test with a cut-off value of 38 could reduce the proportion of women hospitalized in Germany from 44.6 to 24.0%, resulting in an expected cost saving of €361 per patient.
The sFlt-1/PlGF ratio test is likely to reduce unnecessary hospitalization of women with a low risk of developing preeclampsia, and identify those at high risk to ensure appropriate management. Even within the restrictions of the DRG system in Germany, this results in substantial cost savings for women with suspected preeclampsia.
KeywordsAngiogenic factors Cost-effectiveness Cost-saving Diagnosis Economic Diagnosis-related group Germany Hospitalization Hypertension Preeclampsia Pregnancy sFlt-1/PlGF
hemolysis, elevated liver enzymes and low platelet count syndrome
length of stay
UK National Institute for Health and Care Excellence
negative predictive value
placental growth factor
Preeclampsia Open Study
PRediction of short-term Outcome in preGNant wOmen with Suspected preeclampsIa Study
fms-like tyrosine kinase 1
Occurring in 6–8% of pregnancies and increasing, hypertensive disorders are the most common cause of maternal death in Europe, contributing to 20–25% of perinatal mortality [1, 2]. In higher income countries increases are attributed to rising obesity and advanced maternal age, trends that are likely to continue [2, 3, 4, 5, 6, 7, 8]. Preeclampsia, defined as new-onset hypertension and proteinuria or other maternal organ dysfunction, after 20 weeks of gestation , complicates approximately 2% of pregnancies [10, 11, 12] and is associated with substantial perinatal morbidity and mortality in mothers and infants .
Preeclampsia/eclampsia accounts for 10–15% of all maternal deaths (more than 70,000 maternal deaths per year worldwide) . Long-term maternal complications of preeclampsia include an increased risk of cardiovascular disease, hypertension, ischemic heart disease, and stroke [13, 14, 15, 16], as well as an increased risk of subsequent type 2 diabetes mellitus [16, 17], ophthalmological complications , end-stage renal disease [19, 20], and death . Adverse outcomes are more common in future pregnancies in women who have experienced preeclampsia [21, 22].
More than 90% of maternal deaths from preeclampsia/eclampsia in Europe are potentially avoidable [23, 24, 25]. Failure to promptly recognize and treat hypertensive disorders of pregnancy, due to the variable clinical presentations and the low predictive value of high blood pressure and proteinuria, contributes to maternal mortality [2, 23, 26]. German Society of Gynecology and Obstetrics guidelines recommend that women with severe hypertension (≥ 160 mmHg systolic or ≥ 110 mmHg diastolic) or apparent preeclampsia are evaluated at the hospital, whereas mild pregnancy-induced hypertension is generally treated in the outpatient clinic . However, diagnostic uncertainty means that women with suspected but not proven preeclampsia may be admitted to hospital unnecessarily, which can lead to substantial healthcare costs in addition to the costs of preeclampsia . Thus, there is a need for rigorously evaluated tests that can predict or rule out preeclampsia with high sensitivity and specificity .
A diagnostic test, which uses the ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) to predict the short-term risk of developing preeclampsia , may help optimize patient management by triaging those at low risk of preeclampsia to an outpatient setting, while ensuring higher-risk patients are managed more intensively. PROGNOSIS (PRediction of short-term Outcome in preGNant wOmen with Suspected preeclampsIa Study), an international, prospective, observational study evaluated the use of sFlt-1/PlGF ratio, as determined by the Elecsys® sFlt-1 and Elecsys® PlGF assays, to predict the short-term (up to 4 weeks) risk of developing preeclampsia [26, 27]. PROGNOSIS derived and validated a cut-off value of 38 whereby: a sFlt-1/PlGF ratio ≤ 38 rules out the occurrence of preeclampsia in the next week with a negative predictive value (NPV) of 99.3% (and 97.9% for rule out within 2 weeks), and a ratio > 38 indicates that there is an increased risk of developing preeclampsia in the next 4 weeks [26, 29].
The economic impact of the test, based on PROGNOSIS data, has been assessed in the UK , and by the UK National Institute for Health and Care Excellence (NICE) to support their decision to include the sFlt-1/PlGF ratio in the new NICE guidelines for preeclampsia . A further health economic assessment was performed in Italy . However, such assessments cannot be extrapolated directly from one healthcare system to another and must be evaluated based on the unique system in each country. The payer system in Germany uses Diagnosis-Related Groups (DRGs) to assign a fixed payment for treatment of a specific condition. Therefore, the objective of this study was to assess the potential economic impact of using the Elecsys® sFlt-1 and Elecsys® PlGF assays for guiding the management of patients with suspected preeclampsia in Germany, and determine if use of the test remained cost-saving even within this DRG payer system. We adapted the cost-effectiveness model developed for the UK to allow us to evaluate the economic impact of the test from the perspective of the German healthcare system.
PROGNOSIS study data
Patient-level data from PROGNOSIS included hospitalization before developing preeclampsia, inpatient length of stay (LOS), the sFlt-1/PlGF test ratio, and diagnosis of preeclampsia. PROGNOSIS evaluated serum sFlt-1/PlGF ratios in 1050 women with suspected preeclampsia between 24 weeks and 36 weeks plus 6 days of gestation [26, 27]. The German Society of Gynecology and Obstetrics guideline was used as guidance for the patient management decisions applicable to Germany . The aim of PROGNOSIS was to derive and validate a cut-off for the use of the sFlt-1/PlGF ratio in the short-term prediction of preeclampsia [26, 27]. During the study, decisions regarding the management of patients were made in the absence of serum ratio levels of sFlt-1/PlGF, due to unavailability [26, 27]. Fetal and maternal preeclampsia-related adverse outcomes, as well as resource use (e.g. planned/unplanned hospital admissions, LOS) were recorded . Each participating study site of PROGNOSIS provided Ethics Committee/Institutional Review Board approval of the study protocol and associated documents (participant informed consent, participant information) before the start of the clinical part of the study. All women provided written informed consent before enrollment [26, 27]. Details of the study sites and Ethics Committee/Institutional Review Board approvals of PROGNOSIS are provided in Additional file 2. Ethics approval and participant consent for this health economics study was not necessary as it involved the use of a previously published de-identified database of PROGNOSIS according to German legislation.
The patient treatment scenarios in this German model were specifically aligned with the German guidelines and the “Mutterschutzrichtlinien” (Maternity guidelines directives). Accordingly, the economic model included four different levels of intensity for management of hypertensive pregnancy disease: (1) outpatient management with regular measurement of blood pressure, determination of body weight, and assessment of proteinuria; (2) low intensity hospital management, with no longer than 1 day of hospitalized treatment; (3) intermediate intensity hospital management, with the period of hospitalization within the mean residence time (i.e. 2–9 days); and (4) high intensity hospital management, involving a period of hospitalization longer than the mean residence time (i.e. ≥ 10 days).
Management of women in Germany based on PROGNOSIS data
Women, % (n)
Management level 1
Management level 2
≥ 1 day hospitalization
Management level 3
2–9 days hospitalization
Management level 4
≥ 10 days hospitalization
Classification by sFlt-1/PlGF ratio
Assumed hospitalization rates in the no-test and test scenario (based on data in German women participating in the PROGNOSIS study)
Distribution between categories
Assumed hospitalization rate
sFlt-1/PlGF ratio ≥ 85 at weeks 20 + 0–33 + 6, or ≥ 110 from week 34 onwards
sFlt-1/PlGF ratio > 38 − < 85 at weeks 20 + 0–33 + 6, or > 38 − < 110 from week 34 onwards
sFlt-1/PlGF ratio ≤ 38
Clinical algorithm development
For the purposes of modeling the test scenario, a clinical algorithm was developed to estimate the disposition of women according to the value of the added ratio [1, 30, 35]. The assumption was that the proportion of women with a test ratio > 38 would be the same as that observed in the German cohort of PROGNOSIS . During PROGNOSIS, test results were not available at the time of doctors’ patient management decisions, but were evaluated afterwards. Table 2 shows the hospitalization rates for the no-test and the assumed hospitalization rates for the test scenarios. Vatish et al. 2016  stated that a ratio ≤ 38 would suggest a low risk of preeclampsia and, in principle, except for emergency situations, that no women would need to be hospitalized to manage the risk. Vatish et al. 2016  continued to note that, in practice, there may be other reasons for hospitalization. Although there are potentially many different reasons that a clinician may make the assessment that a women with a ratio ≤ 38 may need to be hospitalized, unfortunately it was not possible to quantify all of these from the PROGNOSIS data. Thus, for pragmatic reasons, in the economic model we chose one example that was quantifiable from the available data, which was the assumption that a woman would be hospitalized if her blood pressure was higher than 160/110 mmHg. In the German population of PROGNOSIS, 1.5% of women met this blood pressure criterion and had a sFlt-1/PlGF ratio value ≤ 38 (Table 2). The economic model did not assume separate reimbursement for any particular treatments (e.g. corticosteroids, magnesium) given to women with a sFlt-1/PlGF ratio > 38, irrespective of hospitalization, since the German healthcare system is based on diagnostically related groups (i.e. clinics receive a set fee according to the diagnosis); healthcare costs remain the same within one diagnostically related group and the mean residence time irrespective of the treatment received.
Classification by sFlt-1/PlGF ratio after re-test
The economic model includes an option for a re-test 2 weeks after the initial test if the initial test was negative (ratio ≤ 38), they had been managed as an outpatient, and had not developed preeclampsia in the 2 weeks following their initial test. Women who were hospitalized were assumed not to be re-tested. The percentage of women who received a re-test was assumed to be 6.5%, which was derived from the Preeclampsia Open Study (PreOs; a multicenter, prospective, non-interventional study that examined the influence of sFlt-1/PlGF ratio on clinical decision making in the management of pregnant women with suspected preeclampsia in Germany and Austria [36, 37]). In PreOS, investigators were free in their clinical decisions, with no cutoff values recommended or clinical measures/procedures stipulated. However, investigators had access to the package insert for the test and were aware that an sFlt-1/PlGF ratio of ≥ 85 was useful for confirming a diagnosis of preeclampsia . Percentages of women in each test category at re-test and the corresponding hospitalization rates were derived from PROGNOSIS data. During PROGNOSIS, test results were not available at the time of doctors’ patient management decisions, but were evaluated afterwards. Overall, 8.1% of women had a ratio of ≥ 85 at weeks 20 + 0–33 + 6 or a ratio ≥ 110 from week 34 onwards, of whom none were hospitalized; 13.5% of women had a ratio > 38 − < 85 at weeks 20 + 0–33 + 6 or a ratio of > 38 − < 110 from week 34 onwards, of whom 20.0% were hospitalized; and 78.4% of women had a ratio ≤ 38, of whom none were hospitalized.
In line with Vatish et al. 2016 , the cost analysis included the cost of the ratio test (€80), treatment cost of hospitalizations and outpatient appointments, anti-hypertensive medication and regular testing costs, the cost of preventing complications, and the cost of treating complications. Unit costs were taken from German-specific sources . Final costs included a quarterly fee (€115.1) that is paid to outpatient doctors for every pregnant woman covering all examinations recommended by the “Gemeinsamer Bundesausschuss” (Federal Joint Committee) or the “Mutterschutzrichtlinien” (Maternity guidelines directives), multiplied by the average number of quarters (1.2) . This was applied to all patients irrespective of whether they were hospitalized or not, in addition to the weighted total cost per hospitalization (applied to all hospitalized patients), which were based on the DRGs (DRG 2017) O65A and O65B and were calculated by multiplying the costs for low (assuming ≤ 1 day in hospital) (€621.2), intermediate (assuming 2–9 days in hospital) (€1458.5), and high intensity (assuming the average LOS of 15.2 days for hospital stays ≥ 10 days) management (€2840.0) by the proportion of patients managed in each of these settings.
Sensitivity analyses were performed to test the robustness of the results. All scenarios used the German population of PROGNOSIS. The analyses consisted of: (a) variations in inpatient LOS, whereby LOS for hospitalized patients was increased and reduced by 20% (ranging from 12.2 to 18.2 days); (b) increment in hospitalization costs, whereby the average hospitalization costs were increased by 20% (from €1.462 to €1.754) due to the low reimbursement for hospitalization in Germany compared with the actual costs associated with the treatment and compared with other countries; and (c) variations in the proportion of women admitted to hospital depending on the value of the sFlt-1/PlGF ratio. For the latter, variations included a 5-percentage-point increase (from 1.5 to 6.5%) in the proportion of women hospitalized with a ratio of ≤ 38, and a 10-percentage-point variation in the proportion of women hospitalized with a ratio of > 38 − < 85 at weeks 20 + 0–33 + 6 or a ratio of > 38 − < 110 from week 34 onwards (ranging from 47.6 to 67.6%) or a ratio of ≥ 85 at weeks 20 + 0–33 + 6 or a ratio ≥ 110 from week 34 onwards (ranging from 60 to 80%). Furthermore, the effect of introducing a re-test has been analyzed in two different scenarios: (a) including a re-test rate of 6.5% derived from PreOS data for women treated in the outpatient setting who initially had a test result of ≤ 38 and did not develop preeclampsia at week two and (b) a re-test scenario where every woman was retested irrespective of whether she developed preeclampsia and irrespective of the initial sFlt-1/PlGF result.
Results of the cost analysis for the introduction of the sFlt-1/PlGF ratio test
No test, n (%)
Test, n (%)
Patients hospitalized before preeclampsia, n
Subsequently developed preeclampsia, n (%)
Patients not hospitalized before preeclampsia, n
Subsequently developed preeclampsia, n (%)
Total cost, €
Criteria for the re-test scenarios
Re-test rate of 6.5%
Re-test for all women
Applied to all women with the following criteria:
- initially had a test result of ≤ 38
- did not develop preeclampsia at week two
- were treated in an outpatient setting
The influence of the re-test for this population on the clinical and budget impact resulting from a change in management according to the re-test results and the additional test costs has been considered.
The influence of the additional costs on the budget impact for a re-test for all women irrespective of the initial test result, preeclampsia status at week two and treatment location has been taken into account.
The influence of a re-test on the clinical impact resulting from a change in management according to the re-test results and the additional test costs has only been considered for all women with the following criteria:
- initially had a test result of ≤ 38
- did not develop preeclampsia at week two
- were treated in an outpatient setting
This economic analysis of patient-level data from the German cohort in the PROGNOSIS study demonstrates that even within the restrictions of this DRG payer system, use of the sFlt-1/PlGF ratio in women with suspected preeclampsia remains cost-saving, with an expected saving of €361 per patient. As for any such test, in order for payers to justify use of the test, country-specific health economics calculations are necessary to demonstrate the impact on healthcare budgets. The sFlt-1/PlGF ratio has previously been shown to improve the prediction of preeclampsia in women with suspected preeclampsia [26, 27] and, as a consequence, its use has been demonstrated to provide potential cost-savings for healthcare systems in the UK and Italy [30, 32]. Given that the annual number of live-born and stillbirths in Germany in 2015 was 740,362 , which we estimate to arise from approximately 726,450 pregnancies, and that approximately 15% of pregnant women in Germany develop signs or symptoms of preeclampsia [40, 41], the use of the sFlt-1/PlGF test has the potential to provide an annual cost saving in Germany of more than €39 million.
Our results are similar to those of an economic study, also based on data from PROGNOSIS, which assessed the impact of introducing the sFlt-1/PlGF ratio test into clinical practice in the UK . Introduction of the test in the UK was estimated to reduce the number of women hospitalized by more than half (56%), from 36 to 16%, which was associated with a net cost saving of £344 in the base case analysis . A similar study, in a cohort of 49,455 pregnant women in Italy based on patient-level data derived from PROGNOSIS reported expected net cost savings for the Italian National Health System of €671 per patient . Although all three studies in Germany, the UK and Italy have shown cost-savings, lower cost savings demonstrated in our study in Germany compared with the Italian study are likely due to differences in the health systems in the respective countries; for example, differences in pricing and reimbursement for treatment of hypertensive women and general differences in patient management. The Germany payer system is based on a DRG rate per treatment of a specific disease, so the cost-savings we demonstrated directly reflect the reduced need for hospitalization, rather than cumulative reductions in use of individual interventions or resources for monitoring and treatment of preeclampsia.
Our results, which are based on real-life data, are more conservative than those reported in an earlier economic study from a German payer perspective, based on an assumed cohort of 1000 patients and published clinical data and expert opinion regarding German practice and resource utilization . The study, which utilized a sFlt-1/PlGF ratio cut-off of 85 and assumed that the cost of the test was €34.40, with testing repeated up to three times at six-weekly intervals, demonstrated that introduction of the test was associated with cost savings of €637 per patient. These cost savings were mostly driven by a dramatic 71% reduction in the number of patients who would have been unnecessarily tested, treated and managed for preeclampsia under the standard practice scenario. Moreover, the fact that the study was based on private health insurance costs, which are higher than the public insurance costs used in our study, and that medication costs were based on different German DRGs, all contributed towards the differences in costs savings between this and our study.
A study by Schnettler and colleagues  included women before 34 weeks’ gestation with suspected preeclampsia. The study evaluated standard clinical assessment with and without sFlt-1/PlGF ratio (using a cut-off value of 85) from a US healthcare payer perspective. Base-case results show an overall cost reduction of $1215 per patient, from $3022 to $1807, associated with the use of the sFlt-1/PlGF ratio. Finally, a recent budget impact model using data from a prospective observational cohort study investigating the role of the PlGF test alone for triaging 625 women with suspected preeclampsia in the UK and Ireland, reported a mean cost saving associated with the PlGF test of £635 (95% CI − £1454 to −£4) per woman .
Within the German cohort of the PROGNOSIS study, 44.6% of women with suspected preeclampsia were admitted to hospital, the majority of whom did not subsequently develop preeclampsia (only 29.6% developed preeclampsia). We show that use of sFlt-1/PlGF ratio values of ≤ 38 would reduce the proportion of women hospitalized to 24.0%, which could potentially translate into a substantial reduction in burden on the German healthcare system. Indeed, the Elecsys sFlt-1/PlGF ratio test is already in clinical use in Germany using a cut-off value of 85 to “rule in” preeclampsia . The multicenter, prospective, non-interventional PreOs study examined the influence of sFlt-1/PlGF ratio on clinical decision making in the management of pregnant women with suspected preeclampsia in Germany and Austria [36, 37]. Statistical analysis of outcomes was conducted using sFlt-1/PlGF categories ≤ 33, > 33 to < 85, and ≥ 85, with results from the study indicating that women at highest risk were correctly hospitalized after the sFlt-1/PlGF test, and that the risk for preeclampsia-related maternal and fetal outcomes increased along with increasing sFlt-1/PlGF ratios and was highest in women with an sFlt-1/PlGF ratio of ≥ 85 . Among initially planned hospitalizations in PreOS, approximately one-third (32.5%) were identified as not being necessary in the short term. Results of our study support the results of the PreOs study and provide further evidence for use of the sFlt-1/PlGF test to support preeclampsia management in the German healthcare setting with the DRG payer system.
As with any study, our study has its strengths and limitations. A major strength is that the analysis was based on clinical data collected from a large observational study (PROGNOSIS) and, as such, is likely to reflect real-world clinical practice. Investigators in PROGNOSIS and the PreOS study were specialists in managing women with preeclampsia, therefore actual savings are likely to be higher than estimated here. This is because not all doctors in the real world are specialists for hypertensive disorders in pregnancy. Therefore, one would assume that hospital admissions in real-world clinical practice, especially unnecessary hospital admissions, are likely to be higher. Also, the scenario analyses indicated robustness of the base-case assumptions, with results shown to be sensitive to the hospitalization costs, LOS, and hospitalization rates with a negative test result (sFlt-1/PlGF ratio ≤ 38).
This study has limitations. The number of German women included in the study, and therefore included in our analysis, was relatively small. The overall savings found in this study in women with suspected preeclampsia may have been lower if a patient population with reduced risk, i.e. no clinical suspicion of preeclampsia, had been used in the model. A probabilistic analysis could have been performed to determine the probability that use of the sFlt-1/PlGF ratio remained cost-saving under the influence of uncertainty of the input parameters, however this analysis was not done; therefore, these data are not available. It is also conceded that data from a randomized controlled study, showing the actual impact of predicting preeclampsia with the sFlt-1/PlGF ratio test, are needed to confirm the value of this approach in clinical practice. Additionally, there are some restrictions associated with the analyzed re-test scenarios. The influence of the re-test results on patient management is only considered for the majority of women (including all women who initially had a test result of ≤ 38, did not develop preeclampsia at week two, and were treated in an outpatient setting). Additional test costs are considered for the entire cohort in the second re-test scenario (Table 4).
A major limitation of our study is that the real costs for preeclampsia in Germany are nearly impossible to calculate, as it is extremely difficult to get reliable data. To be as accurate as possible and only compare costs that arose from treating preeclampsia and exclude general care for pregnancies, only the DRGs for hospitalizations associated with preeclampsia that have not led to delivery have been considered (i.e. since the focus of our study was to “rule out” preeclampsia, we only consider the reduction in false-positive hospitalization not the possible additional correct-positive ones). The cost of treatment of women who developed preeclampsia in an outpatient setting could not be taken into consideration, even if they were hospitalized later as this would usually be associated with delivery. The clinical use of the sFlt-1/PlGF ratio for women with suspected preeclampsia would probably result in reduced admissions to neonatal intensive care, presumably by avoiding preterm deliveries. However, since costs for babies and mothers are not linked within the German healthcare system, neonatal costs could not be included in the model. Therefore, the costs used in our study are assumptions, and one would expect that in real life costs and associated savings might be higher.
Furthermore, long-term adverse outcomes in infants, irrespective of the effects of being born prematurely, have also been reported after preeclampsia, including epilepsy, autism, cardiovascular disease, stroke, and endocrine, nutritional and metabolic diseases in childhood [8, 45, 46]. Therefore, it is realistic, when considering the economic impact of preeclampsia, to not only consider costs associated with treatment of preeclampsia and the immediate adverse outcomes for both mother and child, but also those associated with long-term health consequences .
Based on analysis of the German cohort of patients from the PROGNOSIS study, we demonstrate that use of sFlt-1/PlGF ratios of ≤ 38 is likely to reduce unnecessary hospitalization for women with suspected preeclampsia. We further demonstrate that this reduction in healthcare resource utilization translates into substantial cost savings for the German DRG payer system, supporting the sFlt-1/PlGF ratio test in women with suspected preeclampsia in Germany.
The authors would like to thank Caitlin Smare from Parexel for advice and input into the economic model. Medical writing services in the preparation of this manuscript were provided by Andrea Bothwell and Emma McConnell, PhD, on behalf of Gardiner-Caldwell Communications, with funding provided by Roche Diagnostics. The authors would also like to thank all the women who participated in the PROGNOSIS study, and the investigators, recruitment officers, midwives, and midwifery staff who supported the study, in particular at the German study sites.
This health economic study was funded by Roche Diagnostics.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
MH and CW interpreted the data and drafted the manuscript. DS and AS analyzed and interpreted the data and drafted the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Each participating site in the original PROGNOSIS study provided Ethics Committee/Institutional Review Board approval of the study protocol and associated documents (participant informed consent, participant information) before the start of the clinical part of the study. All women provided written informed consent before enrollment (26, 27; Additional file 2). Ethics approval and participant consent for this health economic analysis for Germany was not necessary as this study involved the use of a previously published de-identified database of PROGNOSIS according to German legislation.
Consent for publication
Not applicable (no data from an individual person).
Martin Hund, Cyrill Wolf and Annabel Schroer are employees of Roche Diagnostics.
Dietmar Schlembach has provided counselling services to Roche and has received fees from Roche for lectures.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 3.Bazzano AN, Green E, Madison A, Barton A, Gillispie V, Bazzano LA. Assessment of the quality and content of national and international guidelines on hypertensive disorders of pregnancy using the AGREE II instrument. BMJ Open. 2016, e009189;6Google Scholar
- 6.Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States, 2000-2014. NCHS Data Brief. 2016:1–8.Google Scholar
- 7.Obesity update http://www.oecd.org/health/Obesity-Update-2014.pdf. Accessed June 2018.
- 23.Centre for Maternal and Child Enquiries (CMACE). Saving mother's lives. Reviewing maternal deaths to make motherhood safer: 2006-2008. BJOG. 2011;118(Suppl 1):1–203.Google Scholar
- 24.Esscher A, Binder-Finnema P, Bodker B, Hogberg U, Mulic-Lutvica A, Essen B. Suboptimal care and maternal mortality among foreign-born women in Sweden: maternal death audit with application of the 'migration three delays' model. BMC Pregnancy Childbirth. 2014;14:141.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Hund M, Allegranza D, Schoedl M, Dilba P, Verhagen-Kamerbeek W, Stepan H. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregnancy Childbirth. 2014;14:324.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, Roberts TE, Mol BW, van der Post JA, Leeflang MM, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess. 2008;12:iii–v. 1-270CrossRefGoogle Scholar
- 29.Verlohren S, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, et al. 8 the sFlt-1/PLGF ratio can rule out preeclampsia for up to four weeks in women with suspected preeclampsia: risk factors, prediction of preeclampsia. Pregnancy Hypertens. 2016;5:140–1.CrossRefGoogle Scholar
- 31.PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1–2-3 test, and BRAHMS sFlt-1 Kryptor/ BRAHMS PlGF plus Kryptor PE ratio) https://www.nice.org.uk/guidance/dg23. Published May 2016. Accessed June 2018.
- 32.Frusca T, Gervasi MT, Paolini D, Dionisi M, Ferre F, Cetin I. Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia. J Matern Fetal Neonatal Med. 2016:1–14.Google Scholar
- 34.Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, et al. New gestational phase−specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346–52.CrossRefPubMedGoogle Scholar
- 35.Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, Klein E, Lapaire O, Llurba E, Ramoni A, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45:241–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Klein E, Schlembach D, Ramoni A, Langer E, Bahlmann F, Grill S, Schaffenrath H, van der Does R, Messinger D, Verhagen-Kamerbeek WD, et al. Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia. PLoS One. 2016;11:e0156013.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Central Federal Association of Health Insurance Funds. Bundesbasisfallwert (BBFW) [GKV-Spitzenverband. Bundesbasisfallwert (BBFW)] https://www.gkv-spitzenverband.de/krankenversicherung/krankenhaeuser/budgetverhandlungen/bundesbasisfallwert/bundesbasisfallwert.jsp. Accessed June 2018.
- 39.Directives of the "Gemeinsamer Bundesausschuss" for the medical care during pregnancy and after delivery ("Mutterschaftsrichtlinien") [Richtlinien Des des Gemeinsamen Bundesausschusses über die ärztliche Betreuung während der Schwangerschaft und nach der Entbindung („Mutterschafts-Richtlinien“)] https://www.g-ba.de/downloads/62-492-1223/Mu-RL_2016-04-21_2016-07-20.pdf. Accessed June 2018.
- 42.Hadker N, Garg S, Costanzo C, van der Helm W, Creeden J. Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective. Hypertens Pregnancy. 2013;32:105–19.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.